CERITINIB

Abbreviation
LDK378
Disease(s)
Non-small lung cancer
Background
.pdf
Patent oppositions filed in
Argentina

Certinib is a kinase inhibitor prescribed for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.

This drug is missing the following documents, can you help us by contributing something?

Oppositions

Information related to relevant oppositions from around the world.

Patent Oppositions

The table includes oppositions aimed at contesting patents covering this drug. Note that at the country level, several patent applications can cover the same drug.

Please pay attention not only to the patent opposition, but also to the patent application it relates to, see column "Related Patent Application". To better identify similarities, the column "Patent Type" indicates a general classification of the patent. Arguments used to contest a specific type of patent may apply for another that fits in the same category.

CountryDateWho FiledOpposition typeOpposition statusPatent typeRelated patent applicationMore info
Argentina13-03-2017CILFAPre-GrantUnder ExaminationFormulationsAR100625A1View/Comment

Is something missing? Help us by contributing missing data: Contribute

↑ Back to Top